2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.07 Immunotherapy in Metastatic Pulmonary Lymphoepithelioma-Like Carcinoma

Pdf Summary

The document discusses the application of immunotherapy in treating metastatic pulmonary lymphoepithelioma-like carcinoma (pLELC), a rare subtype of non-small cell lung cancer (NSCLC). While PD-1/PD-L1 checkpoint inhibitors are commonly used in NSCLC treatment, chemotherapy continues to be the primary treatment for pLELC due to its underrepresentation in major immunotherapy trials. Therefore, the accumulation of efficacy data on immunotherapy for pLELC is crucial.<br /><br />The study involved a cohort from a single tertiary institution, covering cases from 2010 to 2023. It focused on patients with recurrent or metastatic pLELC, using descriptive and survival analysis, specifically the Kaplan-Meier method and log-rank test. The cohort's baseline demographics indicated a median age of 65 years, with 77% female participants. Notably, 81% of participants were non-smokers, and the majority lacked known driver mutations.<br /><br />Immunotherapies examined included Pembrolizumab, Atezolizumab, and Nivolumab. The study's discussion highlights that the progression-free survival (PFS) and overall survival (OS) data for pLELC patients treated with immunotherapy were comparable to figures from major NSCLC trials such as KEYNOTE-024, CheckMate-057, and OAK. <br /><br />Results suggest that given the rarity of driver mutations in pLELC, immunotherapy either as monotherapy or in combination could potentially become the standard treatment, similar to NSCLC cases lacking driver mutations. The study presents a detailed comparison of median PFS and OS across different lines of treatment and aligns them with outcomes from pivotal NSCLC trials, underscoring the viability of immunotherapy as a treatment alternative for pLELC.

Asset Subtitle

Chun Yee Ryan Ho

Meta Tag

Speaker Chun Yee Ryan Ho

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

immunotherapy

metastatic pulmonary lymphoepithelioma-like carcinoma

pLELC

non-small cell lung cancer

NSCLC

PD-1/PD-L1 checkpoint inhibitors

chemotherapy

Kaplan-Meier method

progression-free survival

overall survival